![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif)
Pharmacotherapy Price Comparison
Julienne K. Kirk, PharmD
Arch Fam Med. 1995;4(9):811.
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif) |
A number of short-course pharmacotherapy regimens are now available for the treatment of vaginal candidiasis that can improve patient compliance (Table). In 85% to 90% of cases, Candida albicans is the causative organism.1 Single-dose, orally administered fluconazole (150-mg tablet) has recently been approved by the Food and Drug Administration for treatment of vaginal candidiasis. Adequate controlled studies have shown single-dose fluconazole to be as effective as other common treatments for vaginal candidiasis.2 Oral administration of fluconazole in a single dose can cause nausea, vomiting, abdominal pain, and diarrhea.
. . . [Full Text PDF of this Article]
Author Affiliations
Bowman Gray School of Medicine Winston-Salem, NC
|